- Home
- COEP vs HOWL Comparison
COEP vs HOWL Comparison
Compare COEP & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- HOWL
- Stock Information
- Founded
- COEP 2017
- HOWL 2017
- Country
- COEP United States
- HOWL United States
- Employees
- COEP N/A
- HOWL N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- HOWL Health Care
- Exchange
- COEP Nasdaq
- HOWL Nasdaq
- Market Cap
- COEP 39.0M
- HOWL 37.9M
- IPO Year
- COEP N/A
- HOWL 2021
- Fundamental
- Price
- COEP $9.31
- HOWL $0.99
- Analyst Decision
- COEP
- HOWL Strong Buy
- Analyst Count
- COEP 0
- HOWL 3
- Target Price
- COEP N/A
- HOWL $8.33
- AVG Volume (30 Days)
- COEP 107.6K
- HOWL 270.1K
- Earning Date
- COEP 05-27-2025
- HOWL 05-08-2025
- Dividend Yield
- COEP N/A
- HOWL N/A
- EPS Growth
- COEP N/A
- HOWL N/A
- EPS
- COEP N/A
- HOWL N/A
- Revenue
- COEP N/A
- HOWL $1,143,000.00
- Revenue This Year
- COEP N/A
- HOWL N/A
- Revenue Next Year
- COEP N/A
- HOWL $733.33
- P/E Ratio
- COEP N/A
- HOWL N/A
- Revenue Growth
- COEP N/A
- HOWL N/A
- 52 Week Low
- COEP $2.31
- HOWL $0.60
- 52 Week High
- COEP $13.70
- HOWL $5.73
- Technical
- Relative Strength Index (RSI)
- COEP 49.50
- HOWL 55.55
- Support Level
- COEP $7.81
- HOWL $0.80
- Resistance Level
- COEP $10.86
- HOWL $1.07
- Average True Range (ATR)
- COEP 1.45
- HOWL 0.09
- MACD
- COEP 0.09
- HOWL 0.02
- Stochastic Oscillator
- COEP 62.07
- HOWL 70.37
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.